Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: A single-center with homogeneous treatment experience.

Moraima JiménezSabela BobilloVerónica PonsCarla SánchezAna PérezAntonieta MoleroNayibe MirandaÁngela SánchezElizabeth TabaresFrancesc BoschDavid Valcárcel

Published in: Transfusion (2022)

Our experience confirms improvement in the outcomes with a decrease in refractoriness and mortality since the introduction of caplacizumab.

Keyphrases

cardiovascular events
metabolic syndrome
adipose tissue
big data
replacement therapy
smoking cessation
glycemic control